Oral Vinorelbine Plus Cisplatin as First-Line Chemotherapy in Nonsquamous Non-Small-Cell Lung Cancer: Final Results of an International Randomized Phase II Study (NAVotrial 01)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064211%3A_____%2F14%3A%230000392" target="_blank" >RIV/00064211:_____/14:#0000392 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.cllc.2014.04.007" target="_blank" >http://dx.doi.org/10.1016/j.cllc.2014.04.007</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.cllc.2014.04.007" target="_blank" >10.1016/j.cllc.2014.04.007</a>
Alternative languages
Result language
angličtina
Original language name
Oral Vinorelbine Plus Cisplatin as First-Line Chemotherapy in Nonsquamous Non-Small-Cell Lung Cancer: Final Results of an International Randomized Phase II Study (NAVotrial 01)
Original language description
The combination of oral vinorelbine plus cisplatin has been studied in numerous trials as first-line treatment of patients with non-small cell lung cancer (NSCLC) regardless of histologic subtype. NAVoTrial 01 is the first study that explores this combination specifically in nonsquamous (NS) NSCLC by assessing the feasibility of this doublet (ratio 1:2) in an investigational approach. A reference arm with pemetrexed plus cisplatin was included. Maintenance therapy with single-agent therapy after 4 cycles of combination therapy was included in the study schedules because it reflected a trend in first-line treatment of NSCLC.Patients and Methods Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m² and cisplatin 75 mg/m² on day 1 (arm A) or oral vinorelbine 80 mg/m² on days 1 and 8 (first cycle 60 mg/m²) and cisplatin 80 mg/m² on day 1 (arm B). After 4 cycles, patients without disease progression received single-a
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FF - ENT (ie. ear, nose, throat), ophthalmology, dentistry
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Lung Cancer
ISSN
1525-7304
e-ISSN
—
Volume of the periodical
15
Issue of the periodical within the volume
4
Country of publishing house
IE - IRELAND
Number of pages
8
Pages from-to
258-265
UT code for WoS article
000338412800002
EID of the result in the Scopus database
—